Phase 2 Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."

T2023-004 Phase 2 Trial of Revumenib (SNDX-5613) in Combination With FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged Acute Myeloid Leukemia

The goal of this clinical trial is to learn if Revumenib in combination with Fludarabine and Cytarabine can treat children with NUP98-rearranged relapsed or refractory Acute Myeloid Leukemia. The main question it aims to answer is:

What is the Best Overall Response Rate by morphologic response criteria after up to two cycles of revumenib in combination with fludarabine and cytarabine (FLA) chemotherapy?

Participants will receive up to two cycles of Revumenib in combination with fludarabine and cytarabine with intrathecal triple therapy. Participant may also receive a stem cell transplant followed by Revumenib monotherapy if it is necessary.

Up to 27 children and young adults will be enrolled.

Study Overview

• Status: Not yet recruiting
• Conditions: Leukemia, Myeloid, Acute
• Intervention / Treatment: Drug: Revumenib; Drug: Fludarabine; Drug: Cytarabine (Ara-C); Drug: Methotrexate (IT); Drug: Hydrocortisone (intrathecal); Drug: Cytarabine (intrathecal)

• Study Type: Interventional
• Enrollment (Estimated): 24
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Age Patients must be > 30 day and < 22 years of age at time of enrollment.

Diagnosis Patients must have NUP98-r AML (according to WHO Classification of Hematolymphoid Tumors (5th Edition)) that is either refractory to or is in first relapse following initial therapy. Documentation of prior known NUP98-r AML is sufficient.

Definition of relapsed disease:

• Recurrent disease with ≥ 5% leukemic blasts by morphology in the bone marrow after having achieved morphologic remission (morph-CR). Patients who have received any other re-induction therapy following relapse will not be eligible.
• Morph-CR is defined as attainment of an M1 bone marrow (< 5% morphologic leukemic blasts) no evidence of circulating leukemic blasts or extramedullary disease and with recovery of peripheral blood counts (ANC ≥ 500/µL and platelet count ≥ 50,000/µL).

Definition of primary refractory disease:

Refractory disease with ≥ 5% leukemic blasts by morphology in the bone marrow after one attempt at remission induction, which may consist of up to two different therapy courses (e.g., COG AAML1831 de novo therapy including Induction I and Induction II). Patients must not have received more than one remission induction remission attempt.

Performance Level Patients must have a performance status corresponding to ECOG scores of 0, 1 or 2 (> 50 Lansky or Karnofsky score). Use Karnofsky for patients > 16 years of age and Lansky for patients ≤ 16 years of age (Appendix I). Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

CNS Disease Patients may have status of CNS1, CNS2, or asymptomatic CNS3 disease. Patients with symptomatic CNS 3 disease are ineligible.

HIV-Infection HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial, provided antiretroviral therapy does not have clinically significant drug-drug interactions with revumenib.

Prior Therapy:

Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment.

1. Cytotoxic Chemotherapy: Must not have received within 14 days of entry onto this study, except for hydroxyurea or corticosteroids.

   NOTE: Cytoreduction with hydroxyurea must be discontinued prior to the start of protocol therapy. Use of hydroxyurea or steroids for differentiation syndrome, premedication to prevent allergic reaction, physiologic steroids or during anesthesia is allowed

2. Antibodies: ≥ 21 days must have elapsed from infusion of last dose of an antibody-drug conjugate. For unmodified antibodies or T cell engaging antibodies, 2 half-lives must have elapsed before enrollment. Any toxicity related to prior antibody therapy must be recovered to Grade ≤ 1.
3. Interleukins, Interferons and Cytokines (other than Hematopoietic Growth Factors): ≥ 21 days after the completion of interleukins, interferon or cytokines (other than Hematopoietic Growth Factors).
4. Hematopoietic Growth Factors: ≥ 14 days after the last dose of a long-acting growth factor (e.g., pegfilgrastim) or ≥ 7 days for short acting growth factor.

5. Radiation Therapy (RT):

   • 14 days have elapsed for local palliative RT (small port);
   • ≥ 84 days must have elapsed if prior craniospinal RT or if ≥ 50% radiation of pelvis;
   • ≥ 42 days must have elapsed if other substantial BM radiation.

6. Stem Cell Infusions:

   • ≥ 84 days since allogeneic (non-autologous) bone marrow or stem cell transplant (with or without TBI) or boost infusion (any stem cell product; not including DLI);
   • No evidence of graft versus host disease (GVHD) with the exception of Grade 1 GVHD.
7. Cellular Therapy: ≥ 28 days after the completion of DLI (donor lymphocyte infusion) or any type of cellular therapy (e.g. modified T cells, NK cells, dendritic cells, etc.).

NOTE: Potential subjects who have received an intervention intended to treat their primary malignancy which does not fall into one of the above categories will require a minimum 30 day washout from that intervention and the patient must be discussed with the Study Chair or designee who may determine a longer washout period as necessary.

NOTE: Intrathecal chemotherapy: No waiting period is required for patients having received any combination of intrathecal therapy (cytarabine, methotrexate, and/or corticosteroids).

Organ Function Requirements

dequate Renal Function Defined as: Patient must have a calculated creatinine clearance or radioisotope GFR ≥ 60ml/min/1.73m2.

Adequate Liver Function Defined as:

• Total bilirubin (sum of conjugated + unconjugated) ≤ 1.5x institutional upper limit of normal for age (unless attributable to leukemic involvement), and
• SGPT (ALT) and SGOT (AST) must be ≤ 3x institutional upper limit of normal (unless attributable to leukemic involvement).

Adequate Cardiac Function at Screening, Defined as:

• Ejection fraction (EF) of ≥ 50% or if EF unavailable, shortening fraction (SF) ≥ 28% by echocardiogram. AND
• Corrected QT (using Fridericia's correction [QTcF]) interval < 450 msecs. See Appendix II for directions on calculating QTcF.

NOTE: There are no specific electrolyte parameters for eligibility. However, it should be noted that, to limit QTc prolongation risk, patients must maintain adequate potassium and magnesium levels to initiate and continue revumenib on protocol therapy. See section 4.1.2.1 for electrolyte monitoring.

Reproductive Function

• Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 72 hours prior to enrollment.
• Female patients with infants must agree not to breastfeed their infants while on this study and for one week after the last revumenib dose.
• Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for up to 4 months (16 weeks) after the last dose of revumenib.

Anti-GVHD or Agents to Prevent Organ Rejection Post-Transplant

• Patients who are receiving systemic cyclosporine, tacrolimus, or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post transplant are eligible to enroll in the trial provided that htey do not have active GVHD (other than Grade 1)

Exclusion Criteria:

Isolated Extramedullary Disease: Patients with isolated extramedullary disease are ineligible.

Prior diagnosis of acute lymphoblastic leukemia: Patients experiencing lineage switch to AML will not be eligible for this study.

CNS3 Disease with clinical signs or neurologic symptoms suggestive of CNS leukemia at time of relapse, such as facial nerve palsy, brain/eye involvement or hypothalamic syndrome.

Infection: Patients with documented active, uncontrolled infection at the time of study enrollment.

Patients are excluded if they have:

• Positive blood culture within 48 hours of study enrollment;
• Fever above 38.2⁰ C within 48 hours of study enrollment with clinical signs of infection. NOTE: Fever that is determined to be due to tumor burden does NOT exclude patients if there are documented negative blood cultures for at least 48 hours prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability.
• A positive fungal culture within 30 days of study enrollment.
• Active fungal, viral, bacterial, or protozoal infection requiring IV treatment. Chronic prophylaxis therapy to prevent infections does not exclude patients.

Cardiac: Patients with a history of congenital prolonged QT syndrome, congestive heart failure, or uncontrolled arrhythmia in the past 6 months prior to study enrollment.

Gastrointestinal issues: Patients with gastrointestinal issues of the upper gastrointestinal tract that might affect oral drug absorption.

Prior menin inhibitor therapy

Patients with active GVHD (other than Grade 1) are ineligible to enroll.

Concomitant Medications CYP3A4 Inhibitors/Inducers: Systemically administered moderate or strong CYP3A4 inducers or strong CYP3A4 inhibitors should be discontinued 7 days prior to enrollment with the following exceptions: itraconazole, ketoconazole, posaconazole, or voriconazole.

Corticosteroids: Patients who are receiving systemic corticosteroids are not eligible except when given as physiologic dosing or as allowed in inclusion criteria.

Investigational Drugs: Patients who are receiving another investigational drug (for a time frame less than the 5 half-life periods of the respective investigational drug) are not eligible.

QTc Prolonging Agents: Medications with a known risk of Torsades de Pointes (TdP) are prohibited, with the exception of drugs that are used as standard supportive therapies (listed below). Medications with a possible or conditional risk of TdP are allowed. Consult CredibleMeds® at https://crediblemeds.org/ for risk classifications.

Medications with a known risk of TdP used as standard supportive therapies that are allowed for concomitant use: azithromycin, ciprofloxacin, fluconazole, levofloxacin, methadone (allowed if chronic, scheduled use > 2 weeks prior to revumenib initiation; do not initiate methadone during protocol treatment), ondansetron, pentamidine, and propofol.

See Appendix II for Cardiac Monitoring Guidelines Patients with a contraindication or unable to tolerate at least one of the following medications utilized for antifungal prophylaxis: itraconazole, ketoconazole, posaconazole, or voriconazole.

Patients will be excluded if they have a known allergy to any of the drugs used in the study.

Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with the protocol treatment or procedures, interfere with consent, study participation, follow up, or interpretation of study results.

Patients with DNA fragility syndromes (such as Fanconi anemia, Bloom syndrome) are excluded.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Part 1; Revumenib -Days 1-28 Fludarabine -Days 1-5 Cytarabine -Days 1-5 IT Therapy Triples (Methotrexate, Hydrocortisone, Cytarabine) -Day 0. May receive with marrow done at the end of the previous course. For CNS2 and CNS3 patients, in Cycle 1 continue weekly for 3 to 6 total doses or until 3 negative CSF samples, whichever comes first.

Drug: Revumenib; Patients under 40 kg, and those unable to swallow pills, must receive oral suspension (40 mg/mL): < 40 kg: 95 mg/m2 (max 160 mg/dose) orally twice daily; ≥ 40 kg (flat-dose): 160 mg orally twice daily; Round to the nearest markings on the syringe, within 10% of the calculated dose Patients ≥ 40 kg that are able to swallow pills: - 160 mg orally twice daily; Drug: Fludarabine; 5 mg for patients with BSA 0.25-0.29; 6.25 mg for patients with BSA 0.3-0.34; 8.75 mg for patients with BSA 0.35-0.39; 10 mg for patients with BSA 0.4-0.44; 12.5 mg for patients with BSA 0.45-0.49; 15 mg for patients with BSA 0.5-0.54; 16.25 mg for patients with BSA 0.55-0.59; 30 mg/m2/dose for patients with BSA > 0.6; Drug: Cytarabine (Ara-C); 300 mg for patients with BSA 0.25-0.29; 420 mg for patients with BSA 0.3-0.34; 560 mg for patients with BSA 0.35-0.39; 680 mg for patients with BSA 0.4-0.44; 820 mg for patients with BSA 0.45-0.49; 960 mg for patients with BSA 0.5-0.54; 1100 mg for patients with BSA 0.55-0.59; 2000 mg/m2/dose for patients with BSA > 0.6; Drug: Methotrexate (IT); Given intrathecally; 6 mg for patients > 30 days - < 1 year; 8 mg for patients > 1 - < 2 years; 10 mg for patients > 2 - < 3 years; 12 mg for patients > 3 years; Drug: Hydrocortisone (intrathecal); Given intrathecally; 12 mg for patients > 30 days - < 1 year; 16 mg for patients > 1 - < 2 years; 20 mg for patients > 2 - < 3 years; 24 mg for patients > 3 years; Drug: Cytarabine (intrathecal); Given intrathecally; 18 mg for patients > 30 days - < 1 year; 24 mg for patients > 1 - < 2 years; 30 mg for patients > 2 - < 3 years; 36 mg for patients > 3 years

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Best Overall Response Rate (BOR) by morphologic response criteria	The best Overall Response rate according to morphologic response (Morph-CR/CRi/CRp) after up to 2 cycles	At the end of Cycle 1 and Cycle 2 (each cycle is 28 days)

Collaborators and Investigators

• Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Study record dates

Study Major Dates

• Study Start (Estimated): August 31, 2026
• Primary Completion (Estimated): December 31, 2029
• Study Completion (Estimated): December 31, 2030

Study Registration Dates

• First Submitted: June 25, 2026
• First Submitted That Met QC Criteria: July 2, 2026
• First Posted (Actual): July 7, 2026

Study Record Updates

• Last Update Posted (Actual): July 7, 2026
• Last Update Submitted That Met QC Criteria: July 2, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Histologic Type; Hematologic Diseases; Leukemia, Myeloid; Leukemia; Hemic and Lymphatic Diseases; Leukemia, Myeloid, Acute; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Polycyclic Compounds; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Pregnanes; Steroids; Fused-Ring Compounds; Nucleosides; Pterins; Pteridines; Arabinonucleosides; Aminopterin; Pregnenediones; Pregnenes; 11-Hydroxycorticosteroids; Hydroxycorticosteroids; Adrenal Cortex Hormones; 17-Hydroxycorticosteroids; Methotrexate; Cytarabine; Hydrocortisone; fludarabine; revumenib
• Other Study ID Numbers: T2023-004

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No